| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 47.75 | -0.05 (-0.10%) | 38.72 - 50.16 | 11.8 million (Below Avg) |
Market data as of 4:00PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 47.88 |
|---|---|
| Previous Close | 47.80 |
| Day's Range | 47.66 - 48.05 |
| Market Cap | 144.2B |
| Avg Volume (10 Day) | 26.7M |
| Price/Earnings (Trailing 12 Mo.) | 24.5x |
| Earnings Per Share (Trailing 12 Mo.) | 1.95 |
| Dividend Yield | 0.43 (3.60%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
InSite Vision Announces Joint Patent Infringement Lawsuit with Merck Against Mylan Pharmaceuticals
Business Wire - Monday 06/17/2013 8:30 AM ET
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
PR Newswire - Monday 06/17/2013 8:00 AM ET
Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines
Business Wire - Wednesday 06/12/2013 8:00 AM ET
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
Business Wire - Sunday 06/02/2013 11:15 AM ET
Merck to Present at the Sanford C. Bernstein Strategic Decisions Conference
Business Wire - Thursday 05/30/2013 8:30 AM ET
Agere Augments Leadership with Pharmaceutical Manufacturing and Supply Chain Expert
Business Wire - Wednesday 05/29/2013 10:59 AM ET
Merck Announces Third-Quarter 2013 Dividend
Business Wire - Tuesday 05/28/2013 3:33 PM ET
Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
Business Wire - Thursday 05/23/2013 5:00 PM ET
| MRK | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -4.13% | |
| Net Income Growth (1yr) | -13.26% | |
| Total Debt/Equity | 0.39 | |
| LT Debt/Equity | 0.30 | |
| Earnings Yield | 4.08% | |
| Price/Sales | 3.12 |
| Company | Last | Change |
|---|---|---|
| Sanofi SA | 54.56 | -0.84% |
| GlaxoSmithKline PLC | 52.47 | -0.51% |
| Novartis AG | 73.12 | -0.23% |
| Pfizer Inc | 29.40 | +0.82% |
| Bristol-Myers Squibb Co | 46.85 | +0.88% |
Data is delayed by at least 15 min.